Skip to main content
Top

Journal of Cancer Research and Clinical Oncology

Issue 4/2003

Content (9 Articles)

Original Paper

Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF

Rainer Girgert, Josefa Wittrock, Sabine Pfister, Paul Schweizer

Rapid Communication

EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy

Christine Solbach, Marc Roller, Kai Budischewski, Sibylle Loibl, Maria Nicoletti, Manfred Stegmueller, Manfred Kaufmann

Original Paper

Angiogenin in sera as an independent prognostic factor in gastric cancer

Shouji Shimoyama, Michio Kaminishi

Original Paper

Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance

N. Kato, J. Watanabe, T. Jobo, Y. Nishimura, T. Fujisawa, Y. Kamata, H. Kuramoto

Original Paper

Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer

L. M. Berstein, A. E. Tchernobrovkina, V. B. Gamajunova, A. J. Kovalevskij, D. A. Vasilyev, O. F. Chepik, E. A. Turkevitch, E. V. Tsyrlina, S. J. Maximov, L. A. Ashrafian, J. H. H. Thijssen

Original Paper

Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III

Kathrin Niemöller, Christian Jakob, Ulrike Heider, Ivana Zavrski, Jan Eucker, Olaf Kaufmann, Kurt Possinger, Orhan Sezer

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine